Our first step towards unlocking lung cancer was learning to differentiate the disease subtypes such as small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Our robust menu of tissue diagnostics, liquid biopsies for sustainable monitoring, in addition to immunohistochemistry (IHC) diagnostic assays and staining products, clinical reagents and fully automated staining platforms ensure highly sensitive and accurate diagnostic results to support treatment decisions.
NSCLC responds significantly better to targeted treatments. New immunotherapy (using the body’s own immune cells to attack cancer cells) has demonstrated great promise for patients with SCLC and advanced NSCLC. This type of personalized medicine is providing hope for patients already diagnosed with lung cancer with drugs that are effective based on specific characteristics of their tumor. Key biomarkers with known targeted therapies that today can be detected with diagnostics systems include ALK, EGFR, MET, PD-L1, RET and ROS1.